Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

The activation of lymphocytes by gefitinib treatment has been described. In this phase II pilot trial, we explored the possible synergism between IL-2 and gefitinib for non-small cell lung cancer (NSCLC) treatment. From September, 2003, to November, 2006, 70 consecutive patients with advanced, progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bersanelli, Melissa, Buti, Sebastiano, Camisa, Roberta, Brighenti, Matteo, Lazzarelli, Silvia, Mazza, Giancarlo, Passalacqua, Rodolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276955/
https://www.ncbi.nlm.nih.gov/pubmed/25271833
http://dx.doi.org/10.3390/cancers6042035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276955/
https://www.ncbi.nlm.nih.gov/pubmed/25271833
http://dx.doi.org/10.3390/cancers6042035

Ejemplares similares